Results 151 to 160 of about 1,856,875 (191)

Soluble Urokinase Plasminogen Activator Receptor as a Predictor of All-Cause Death in Patients Undergoing Coronary Angiography at 10-Year Follow-Up. [PDF]

J Clin Med
Kern A, Stompór T, Bojko K, Sienkiewicz E, Pawlak S, Pawlak K, Pawlak D, Poskrobko G, Andrasz E, Gromadziński L, Jalali R, Onichimowski D, Piwko G, Zalewski A, Bil J.   +14 more
europepmc   +1 more source

Soluble urokinase plasminogen activator receptor levels predict survival in patients with portal hypertension undergoing TIPS. [PDF]

JHEP Rep
Loosen SH, Benz F, Mohr R, Reuken PA, Wirtz TH, Junker L, Jansen C, Meyer C, Praktiknjo M, Wree A, Reißing J, Demir M, Gu W, Vucur M, Schierwagen R, Stallmach A, Kunstein A, Bode J, Trautwein C, Tacke F, Luedde T, Bruns T, Trebicka J, Roderburg C.   +23 more
europepmc   +1 more source

Correction: Soluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin‑treated breast cancer patients: a prospective exploratory study. [PDF]

Cardiooncology
Chu J, Tung L, Atallah I, Wei C, Cobleigh M, Rao R, Feinstein SB, Usha L, Banach K, Reiser J, Okwuosa TM.   +10 more
europepmc   +1 more source

The Predictive Role of C-Reactive Protein, Leukocyte Cell Count, and Soluble Urokinase Plasminogen Activator Receptor for Pulmonary Sequelae in Hospitalized COVID-19 Survivors: A Prospective Single-Center Cohort Study. [PDF]

J Clin Med
Altintas I, Kallemose T, Lindstrøm MB, Parvaiz I, Rokkedal I, Rasmussen LJ, Iversen KK, Eugen-Olsen J, Iversen KK, Hansen EF, Ulrik CS, Nehlin JO, Andersen O.   +12 more
europepmc   +1 more source

Post-COVID-19 Multisystem Inflammatory Syndrome in Adults (MIS-A) With Elevated Levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) Treated With Anakinra: A Case Report. [PDF]

Cureus
Christaki M, Samanidou V, Liontos A, Konstantopoulou R, Milionis H.   +4 more
europepmc   +1 more source

Soluble urokinase plasminogen activator receptor (suPAR) in bronchoalveolar fluid and blood in critically ill patients-a prospective cohort study. [PDF]

Infection
Reisinger AC, Hatzl S, Prattes J, Hackl G, Schilcher G, Eisner F, Niedrist T, Raggam R, Krause R, Eller P.   +9 more
europepmc   +1 more source

Soluble urokinase plasminogen activator receptor (suPAR) is a potential biomarker of stage III-IV, grade C periodontitis through the impact of post-radiotherapy on head and neck cancer patients. [PDF]

BMC Oral Health
Al-Kubaisi AA, Ghazi MA, Majeed NS, Aldelaimi ER, Enezei HH.   +4 more
europepmc   +1 more source

Soluble urokinase Plasminogen Activator Receptor (suPAR) mediates the effect of a lower education level on adverse outcomes in patients with coronary artery disease. [PDF]

Eur J Prev Cardiol
Füller D, Liu C, Ko YA, Alkhoder AA, Desai SR, Almuwaqqat Z, Patel SA, Ejaz K, Kauser T, Martini MA, Alvi Z, Mehta PK, Sperling LS, Quyyumi AA.   +13 more
europepmc   +1 more source

Association between the Serum Soluble Urokinase Plasminogen Activator Receptor and Peripheral Arterial Stiffness According to the Cardio-Ankle Vascular Index in Patients Undergoing Kidney Transplantation. [PDF]

Rev Cardiovasc Med
Yang HH, Chen YC, Ho CC, Hsu BG.
europepmc   +1 more source

Role of soluble urokinase plasminogen activator receptor in critically ill children with hospital-acquired pneumonia: an observational study in hospital with controls. [PDF]

BMJ Paediatr Open
Saleh NY, Soliman SE, Aboukoura MA, Garib MI.   +3 more
europepmc   +1 more source